129 related articles for article (PubMed ID: 37772592)
1. Effective Use of Bromelain and Acetylcysteine (BromAc
Skalkos E; Chen KL; Wijayawardana R; Morris DL
Anticancer Res; 2023 Oct; 43(10):4735-4738. PubMed ID: 37772592
[TBL] [Abstract][Full Text] [Related]
2. Transhepatic Bromelain and Acetylcysteine for Treatment of Posterior Gastric Pseudomyxoma Peritonei: A Case Report.
Sun SL; Sarofim M; Morris DL
Anticancer Res; 2024 May; 44(5):2239-2241. PubMed ID: 38677761
[TBL] [Abstract][Full Text] [Related]
3. Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei.
Lam AR; Bazzi K; Valle SJ; Morris DL
Case Rep Oncol; 2021; 14(1):628-633. PubMed ID: 33976645
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Treatment of Unresectable Pseudomyxoma Peritonei with Multiple Treatments of Intratumoural Bromelain and Acetylcysteine (BromAc
Yang J; Glenn D; Lodh S; Valle S; Morris DL
Case Rep Oncol; 2023; 16(1):1551-1556. PubMed ID: 38074518
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP) caused by low-grade appendiceal mucinous neoplasm (LAMN): a case report.
Geisel D; Langen U; Rüdiger T
J Med Case Rep; 2023 Jun; 17(1):297. PubMed ID: 37381056
[TBL] [Abstract][Full Text] [Related]
6. A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study.
Valle SJ; Akhter J; Mekkawy AH; Lodh S; Pillai K; Badar S; Glenn D; Power M; Liauw W; Morris DL
Eur J Surg Oncol; 2021 Jan; 47(1):115-122. PubMed ID: 31679953
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal BromAc
Mekkawy AH; Breakeit M; Pillai K; Badar S; Akhter J; Valle SJ; Morris DL
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444430
[TBL] [Abstract][Full Text] [Related]
8. Bromelain and acetylcysteine (BromAc
Wen HK; Valle SJ; Morris DL
Am J Cancer Res; 2023; 13(4):1522-1532. PubMed ID: 37168359
[TBL] [Abstract][Full Text] [Related]
9. Complete pathological response of high grade appendicular neoplasm induced Pseudomyxoma Peritonei (PMP) after neoadjuvant intra-peritoneal chemotherapy: A case report.
Padmanabhan N; Ishibashi H; Nishihara K; Sako S; Katayama K; Wakama S; Kamada Y; Yonemura Y
Int J Surg Case Rep; 2020; 72():117-121. PubMed ID: 32534414
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours.
Lansom J; Alzahrani N; Liauw W; Morris DL
Indian J Surg Oncol; 2016 Jun; 7(2):166-76. PubMed ID: 27065707
[TBL] [Abstract][Full Text] [Related]
11. Unusual site of pseudomyxoma peritonei recurrence after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a case report of intraluminal disease manifestation in the small bowel.
Rauwerdink P; Brosens LAA; van Diepen KK; Ghedri ON; Kranenburg O; Boerma D; Witkamp AJ; van Grevenstein HMU
World J Surg Oncol; 2022 May; 20(1):147. PubMed ID: 35538541
[TBL] [Abstract][Full Text] [Related]
12. Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.
Bartoška P; Antoš F; Vítek P; Marx J; Holečková P; Novotný M; Kengbaeva M
Rozhl Chir; 2020; 99(4):159-166. PubMed ID: 32545978
[TBL] [Abstract][Full Text] [Related]
13. Bromelain and acetylcysteine (BromAc
Mekkawy AH; Pillai K; Suh H; Badar S; Akhter J; Képénékian V; Ke K; Valle SJ; Morris DL
Am J Transl Res; 2021; 13(12):13524-13539. PubMed ID: 35035694
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.
Järvinen P; Ristimäki A; Kantonen J; Lepistö A
Scand J Surg; 2013; 102(3):145-51. PubMed ID: 23963027
[TBL] [Abstract][Full Text] [Related]
15. The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study.
Ke K; Pillai K; Mekkawy AH; Akhter J; Badar S; Valle SJ; Morris DL
Discov Oncol; 2021 Aug; 12(1):25. PubMed ID: 35201475
[TBL] [Abstract][Full Text] [Related]
16. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
18. Pseudomyxoma peritonei and an incidental low-grade appendiceal mucinous neoplasm and neuroendocrine appendiceal collision tumour: a case report.
Gupta A; Mirpuri L; Malik F; Hassan H; Amtul N
J Surg Case Rep; 2023 May; 2023(5):rjad281. PubMed ID: 37251256
[TBL] [Abstract][Full Text] [Related]
19. Pseudomyxoma peritonei induced by low-grade appendiceal mucinous neoplasm accompanied by rectal cancer: a case report and literature review.
Ning S; Yang Y; Wang C; Luo F
BMC Surg; 2019 Apr; 19(1):42. PubMed ID: 31023277
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei.
Deraco M; Gronchi A; Mazzaferro V; Inglese MG; Pennacchioli E; Kusamura S; Rizzi M; Anselmi RA; Vaglini M
Tumori; 2002; 88(5):370-5. PubMed ID: 12487553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
